Lataa...
Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action
Eslicarbazepine acetate (ESL) is a once daily antiepileptic drug (AED) approved by the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and Health Canada as an adjunctive therapy in adults with partial-onset seizures (POS). In humans and in relevant animal laboratory species,...
Tallennettuna:
| Julkaisussa: | Pharmacol Res Perspect |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BlackWell Publishing Ltd
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4448990/ https://ncbi.nlm.nih.gov/pubmed/26038700 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.124 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|